Clinical Trial Update: A 12/24-weeks, Open, Multi-centre, Phase IV Study on Safety and Efficacy of 2mg Exenatide Once Weekly (Bydureon) in T2DM Patients. [Phase 4]

View source ↗

Summary

Phase IV trial update assessing safety and efficacy of 2 mg exenatide weekly (Bydureon) in type 2 diabetes mellitus; study completed with posted results in 2019…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Bydureon (exenatide)
• EXENATIDE (EXENATIDE)

Snippet

Sponsor: AstraZeneca | Conditions: Type 2 Diabetes Mellitus | Phase 4 | Status: COMPLETED | Results posted: 2019-05-31